Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk

Arthritis and Rheumatism
Daniel H SolomonSebastian Schneeweiss

Abstract

Controversy persists regarding the cardiovascular risks of treatment with selective cyclooxygenase 2 inhibitors (coxibs) and nonselective nonsteroidal antiinflammatory drugs (NSAIDs). This study was undertaken to examine, in a large group of new users of coxibs and NSAIDs, the rate of cardiovascular events, their time course, and whether baseline cardiovascular risk modified the rate ratios (RRs) for future events. This cohort study included Medicare beneficiaries who enrolled in a state-run prescription drug plan that fully covered NSAIDs and coxibs without restriction. All study patients started use of a coxib or NSAID after January 1, 1999. The primary composite end point was a hospital admission for either myocardial infarction or ischemic stroke. Predefined exposure groups included the 3 coxibs available in the US during the study period (celecoxib, rofecoxib, and valdecoxib), as well as oral formulations of diclofenac, ibuprofen, naproxen, and a composite of all other NSAIDs. We compared the rate of cardiovascular events associated with each of these agents with that in a reference group of patients who did not use NSAIDs or coxibs, but started other medications unrelated to cardiovascular risk. Daily exposure to all stud...Continue Reading

References

Dec 1, 1976·American Journal of Epidemiology·O S Miettinen
Dec 1, 1988·International Journal of Epidemiology·K J Rothman, C Poole
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Feb 24, 2001·The Annals of Thoracic Surgery·G ValenJ Vaage
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
Dec 26, 2001·The New England Journal of Medicine·F Catella-LawsonG A FitzGerald
May 22, 2002·Archives of Internal Medicine·Daniel H SolomonJerry Avorn
May 22, 2002·Archives of Internal Medicine·Douglas J WatsonHarry A Guess
May 22, 2002·Archives of Internal Medicine·Elham RahmeJacques LeLorier
Feb 25, 2003·Lancet·T M MacDonald, L Wei
Jun 28, 2003·The Journal of Thoracic and Cardiovascular Surgery·Elisabeth OttUNKNOWN Ischemia Research and Education Foundation (IREF) Investigators
Oct 31, 2003·American Journal of Epidemiology·Wayne A Ray
Dec 6, 2003·BMJ : British Medical Journal·Jeptha P CurtisHarlan M Krumholz
Dec 25, 2003·American Journal of Epidemiology·Luis Alberto García Rodríguez, Sonia Hernández-Díaz
Jun 16, 2004·Circulation·Luis A García RodríguezAntonio González-Pérez
Feb 17, 2005·The New England Journal of Medicine·Robert S BresalierUNKNOWN Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Feb 17, 2005·The New England Journal of Medicine·Nancy A NussmeierKenneth M Verburg
Apr 20, 2005·Medical Care·Elena Birman-DeychBrian F Gage
Jun 30, 2005·Arthritis and Rheumatism·Daniel H Solomon

❮ Previous
Next ❯

Citations

Nov 22, 2011·Chinese Journal of Integrative Medicine·Yun-xiang CaoYan Zhu
Jan 5, 2008·Current Pain and Headache Reports·Carla R ScanzelloAllan Gibofsky
Nov 26, 2008·Immunology and Cell Biology·Geoffrey A PieterszP Mark Hogarth
Nov 16, 2012·Nature Reviews. Cancer·Asad UmarPeter Greenwald
Dec 2, 2006·Nature Reviews. Drug Discovery·Nick Barker, Hans Clevers
Feb 20, 2008·Journal of Biomolecular Structure & Dynamics·V RajakrishnanGita Subba Rao
Mar 17, 2009·Journal of Public Health·E Chilet-RosellJ F Horga
Nov 12, 2010·QJM : Monthly Journal of the Association of Physicians·H Pieringer, M Pichler
Mar 19, 2013·Rheumatology·Elizabeth J CoulsonHelen E Foster
Feb 7, 2007·Current Opinion in Rheumatology·Carl Turesson, Eric L Matteson
Jul 6, 2007·BMC Gastroenterology·Michael LoydPhilip Jacobs
Dec 4, 2009·Therapeutics and Clinical Risk Management·Gayle McKellar, Gurkirpal Singh
Jan 15, 2014·Vascular Health and Risk Management·Ki Park, Anthony A Bavry
Jan 20, 2010·Journal of Postgraduate Medicine·R Vijayakrishnan
Jun 1, 2006·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Kyung-Soo ChunYoung-Joon Surh
Apr 20, 2014·World Journal of Gastroenterology : WJG·Tae Il Kim
May 7, 2008·Current Rheumatology Reports·Carla R ScanzelloAllan Gibofsky
Nov 6, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Patrick B RyanAbraham G Hartzema
Nov 13, 2013·Expert Opinion on Drug Metabolism & Toxicology·Bhulan Kumar SinghKrishna Kolappa Pillai
Nov 22, 2013·Expert Opinion on Drug Safety·Nicholas MooreAntoine Pariente
Oct 21, 2011·Expert Opinion on Drug Safety·Eric J LavonasRichard C Dart
May 1, 2012·Best Practice & Research. Clinical Gastroenterology·Prarthana Thiagarajan, Janusz A Jankowski
Nov 26, 2008·The American Journal of Medicine·Wolfgang C WinkelmayerDaniel H Solomon
Dec 6, 2007·La Presse médicale·Jean SibiliaGilles Montalescot
Nov 24, 2007·Fundamental & Clinical Pharmacology·Ville-Veikko HynninenKari Laine
Jul 29, 2010·Journal of Evaluation in Clinical Practice·Aneta PerićSandra Vezmar
Oct 6, 2011·Pharmacoepidemiology and Drug Safety·Cristina Varas-LorenzoSusana Perez-Gutthann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.